Financings in Brief: Anika Research
This article was originally published in The Gray Sheet
Executive Summary
Anika Research: Hyaluronic acid products developer and manufacturer enters an agreement with Axiom Venture Partners under which Axiom will pay Anika $2 mil. in exchange for convertible cumulative preferred stock with a 9% dividend rate and warrants to acquire preferred stock. Preferred stock may be converted one-for-one into common shares by the holder. Anika says that prices for the preferred stock and exercise price of warrants will be "the lower of $2 per share or an amount based upon the average closing price of Anika common stock for a specified period prior to the closing of the financing." The financing is expected to close by May 15...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.